Marpai, Inc.
- MRAI · OTC
- Services-Misc Health & Allied Services, NEC
- Tampa, FL
- 107 employees
- CIK 0001844392
Updated from SEC filings through
Top things to know
Executives
-
Damien Lamendola Chief Executive Officer 4, 2026-06-02 -
Steve Andrew Johnson Chief Financial Officer 4, 2026-06-02 - Dallas Scrip Chief Operating Officer 4, 2025-11-12
What leadership is saying
“We believe that these results demonstrate measurable execution on our strategy to build a more resilient, capital-efficient Marpai”
Earnings press release (8-K Ex. 99.1), filed November 12, 2025
Marpai, Inc. is a U.S. public company in services-misc health & allied services, nec (SIC 8090), headquartered in Tampa, FL. It trades as MRAI on OTC. Revenue was $18.1M in the fiscal year ending December 31, 2025, -35.8% from the year before. It reported about 107 employees. Damien Lamendola is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $18.1M 10-K, 2026-03-25 | $28.2M 10-K, 2026-03-25 | $37.2M 10-K, 2025-03-27 | $24.3M 10-K, 2024-03-26 | $14.2M 10-K/A, 2023-07-27 |
| Operating income | -$13.6M 10-K, 2026-03-25 | -$22.1M 10-K, 2026-03-25 | -$28.0M 10-K, 2025-03-27 | -$27.0M 10-K, 2024-03-26 | -$15.9M 10-K/A, 2023-07-27 |
| SG&A | $12.2M 10-K, 2026-03-25 | $14.6M 10-K, 2026-03-25 | $25.8M 10-K, 2025-03-27 | $19.3M 10-K, 2024-03-26 | $13.0M 10-K/A, 2023-07-27 |
| Net income | -$16.6M 10-K, 2026-03-25 | -$22.1M 10-K, 2026-03-25 | -$28.8M 10-K, 2025-03-27 | -$26.5M 10-K, 2024-03-26 | -$16.0M 10-K/A, 2023-07-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Damien Lamendola | Chief Executive Officer | 4, 2026-06-02 |
| Steve Andrew Johnson | Chief Financial Officer | 4, 2026-06-02 |
| Dallas Scrip | Chief Operating Officer | 4, 2025-11-12 |
What Marpai, Inc. does
We are a technology platform company which operates subsidiaries that provide Third Party Administrator (“TPA”), Pharmacy Benefit Management (“PBM”), and value-oriented health plan services to employers that directly pay for employee health benefits.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 26.8 million (as of August 13, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $9.7M (as of June 30, 2025) | 10-K, March 25, 2026 |
| Reportable segments | 1 (period ending December 31, 2025) | 10-K, March 25, 2026 |
| Latest proxy statement | Meeting December 9, 2026 (filed October 23, 2026) | DEF 14A, October 23, 2026 |
| Auditor | Uhy LLP (Melville, New York) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| June 2, 2026 | Steve Andrew Johnson Chief Financial Officer | Buy | 1,100 | $682 | Form 4, June 2, 2026 |
| May 20, 2026 | Yaron Eitan Director | Buy | 10,000 | $3K | Form 4, May 22, 2026 |
| November 7, 2025 | Yaron Eitan Director | Buy | 100,000 | $100K | Form 4, November 12, 2025 |
| November 7, 2025 | Sagiv Shiv Director | Buy | 50,000 | $50K | Form 4, November 12, 2025 |
| November 7, 2025 | Robert M. Pons Director | Buy | 50,000 | $50K | Form 4, November 12, 2025 |
| September 30, 2025 | Damien Lamendola Chief Executive Officer | Buy | 147,058 | $200K | Form 4, October 2, 2025 |
| September 10, 2025 | Damien Lamendola Chief Executive Officer | Buy | 896,903 | $951K | Form 4, September 26, 2025 |
| July 29, 2025 | Damien Lamendola Chief Executive Officer | Buy | 371,470 | $401K | Form 4, August 1, 2025 |
Recent 8-K events
- 8-K filed 2026-07-31
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
- 8-K filed 2026-07-20
- Item 1.01 Entry into a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2026-05-01
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-03-11
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-02-13
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-01-23
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-12-23
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-12
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2025-10-20
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
Frequently asked questions about Marpai, Inc.
- What does Marpai, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a technology platform company which operates subsidiaries that provide Third Party Administrator (“TPA”), Pharmacy Benefit Management (“PBM”), and value-oriented health plan services to employers that directly pay for employee health benefits."
- What is Marpai, Inc.'s revenue?
- $18.1M for the fiscal year ending December 31, 2025, from its 10-K filed March 25, 2026.
- Is Marpai, Inc. profitable?
- Marpai, Inc. reported net income of -$16.6M for the fiscal year ending December 31, 2025.
- How many employees does Marpai, Inc. have?
- About 107, as stated in its annual report.
- Who is the CEO of Marpai, Inc.?
- Damien Lamendola, Chief Executive Officer, as named in a 4 filed June 2, 2026.
- Who is the CFO of Marpai, Inc.?
- Steve Andrew Johnson, Chief Financial Officer, as named in a 4 filed June 2, 2026.
- Where is Marpai, Inc. headquartered?
- Tampa, FL.
- What is Marpai, Inc.'s stock ticker?
- MRAI on OTC.
- What industry is Marpai, Inc. in?
- Services-Misc Health & Allied Services, NEC, SIC code 8090.
- What is Marpai, Inc.'s website?
- marpaihealth.com. Investor relations: https://ir.marpaihealth.com.
- When does Marpai, Inc. report earnings next?
- November 13, 2026. Source: estimate_10q_cadence.
- Is Marpai, Inc. a public company?
- Yes. Marpai, Inc. files with the SEC under CIK 0001844392 and trades as MRAI.
- Who audits Marpai, Inc.?
- Uhy LLP, Melville, New York, as named in its latest annual report (10-K).
- How many shares of Marpai, Inc. are outstanding?
- 26.8 million shares as of August 13, 2026, from its 10-Q filed August 13, 2026.
- What is Marpai, Inc.'s public float?
- $9.7M as of June 30, 2025, as reported on the cover of its 10-K filed March 25, 2026.
- How many business segments does Marpai, Inc. report?
- 1 reportable segment for the period ending December 31, 2025, from its 10-K filed March 25, 2026.
- When is Marpai, Inc.'s annual shareholder meeting?
- December 9, 2026, per its proxy statement (DEF 14A) filed October 23, 2026.
- Have Marpai, Inc. insiders traded stock recently?
- Since July 17, 2025, officers and directors reported 0 open-market sales and 9 purchases worth about $1.9M on Forms 4 and 5. The most recent: Steve Andrew Johnson (Chief Financial Officer) bought 1,100 shares on June 2, 2026.